Related Experiment Videos
[Origin of small cell lung cancers]
V Trillet-Lenoir1, J F Cordier
1Service de pneumologie, hôpital cardiovasculaire et pneumologique Louis-Pradel, Lyon.
La Revue Du Praticien
|April 1, 1993
Summary
Undifferentiated small cell lung cancer, a neuroendocrine tumor, often metastasizes and is sensitive to chemotherapy. Research explores dosage intensification with growth factors to overcome chemoresistance for better outcomes.
Area of Science:
- Oncology
- Cancer Biology
Context:
- Undifferentiated small cell lung cancer (SCLC) presents unique neuroendocrine features.
- SCLC exhibits high metastatic potential and sensitivity to antimitotic drugs.
- Clinical presentation often includes paraneoplastic endocrine syndromes.
Purpose:
- To summarize the distinct characteristics of SCLC.
- To highlight the challenges in managing SCLC metastases.
- To review current and emerging treatment strategies for SCLC.
Summary:
- SCLC's neuroendocrine origin influences its clinical behavior and treatment response.
- Frequent metastases contribute to SCLC's poor prognosis, complicating diagnostic accuracy.
- Standard chemotherapy regimens involve anthracycline, epidophyllotoxin, or platinum salt combinations.
Impact:
- Chemotherapy is the cornerstone of SCLC treatment.
- Dosage intensification using hematopoietic myeloid growth factors shows promise.
- Research into overcoming chemoresistance may lead to improved SCLC survival rates.